Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma.

BACKGROUND Esophageal adenocarcinoma commonly arises from a precancerous condition, Barrett's esophagus, in which the normal squamous epithelium is replaced by a columnar cell-lined epithelium. Genetic alterations occurring in this process could serve as biomarkers for the risk of malignant progression, improve surveillance, and contribute to early diagnosis. We examined two potential biomarkers, cyclin D1 and p53, in a prospective cohort of Barrett's esophagus patients. METHODS A total of 307 patients were enrolled in an endoscopic surveillance cohort, and esophageal biopsy specimens were collected at each endoscopy. Incident cases of adenocarcinoma were matched to control patients within the cohort by duration of follow-up, age, sex, and length of columnar cell-lined epithelium at recruitment. Biopsy specimens were analyzed for cyclin D1 and p53 protein levels by immunohistochemistry. Statistical tests were two-sided. RESULTS A total of 12 cases of adenocarcinoma occurred within the follow-up period, and tumor biopsy specimens from 11 cases stained positive for cyclin D1. Biopsy specimens from eight of these patients taken at recruitment also stained positive for cyclin D1. A case-control analysis of biopsy specimens obtained at recruitment revealed a statistically significantly increased risk of progression to adenocarcinoma in Barrett's esophagus patients whose biopsy specimens were cyclin D1 positive (odds ratio [OR] = 6. 85; 95% confidence interval [CI] = 1.57-29.91; P =.0106) but not in patients whose biopsy specimens were p53 positive (OR = 2.99; 95% CI = 0.57-15.76; P =.197). CONCLUSIONS Cyclin D1-positive staining could be a useful biomarker in identifying Barrett's esophagus patients at high risk of esophageal adenocarcinoma. Given the complexity of genetic alterations in the natural history of this cancer, additional biomarkers will be required to increase the sensitivity and specificity of molecular diagnosis.

[1]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[2]  A. Neugut,et al.  Increased expression of the cyclin D1 gene in Barrett's esophagus. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[3]  Ruggero Montesano,et al.  Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: A review , 1996, International journal of cancer.

[4]  R. Haggitt,et al.  Barrett's esophagus, dysplasia, and adenocarcinoma. , 1994, Human pathology.

[5]  J. Linehan,et al.  p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO‐7 , 1994, The Journal of pathology.

[6]  M. Emond,et al.  Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. , 1996, Oncogene.

[7]  M. Gammon,et al.  Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[8]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[9]  D. Birnbaum,et al.  Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1. , 1995, British Journal of Cancer.

[10]  J. Weissfeld,et al.  Etiology of Barrett's metaplasia and esophageal adenocarcinoma. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  B. Reid,et al.  Barrett's esophagus and esophageal adenocarcinoma. , 1991, Gastroenterology clinics of North America.

[12]  M. Gammon,et al.  Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. , 1997, Journal of the National Cancer Institute.

[13]  J B Wong,et al.  A guide for surveillance of patients with Barrett's esophagus. , 1994, The American journal of gastroenterology.

[14]  C. Cordon-Cardo.  Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. , 1995, The American journal of pathology.

[15]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[16]  C. Hsieh,et al.  Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. , 1998, Gastroenterology.

[17]  C. McConkey,et al.  The rising trend in oesophageal adenocarcinoma and gastric cardia. , 1992, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[18]  P. Hainaut,et al.  Molecular precursor lesions in oesophageal cancer. , 1998, Cancer surveys.

[19]  J. Fraumeni,et al.  Changing patterns in the incidence of esophageal and gastric carcinoma in the United States , 1998, Cancer.

[20]  A. Lindgren,et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.

[21]  S. Spechler.  The columnar-lined esophagus. History, terminology, and clinical issues. , 1997, Gastroenterology clinics of North America.

[22]  T. Hunter,et al.  Cyclins and cancer , 1991, Cell.

[23]  M. Barrett,et al.  Barrett's esophagus: ordering the events that lead to cancer. , 1996, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[24]  Carissa A. Sanchez,et al.  17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. , 1996, Proceedings of the National Academy of Sciences of the United States of America.